Many drug development projects stem from licensing an invention or product. Agreeing on the cost of the license is critical to the licensee to assure that the project is economically feasible. The licensor is interested in maximizing the value of the invention. How do you arrive at the terms? One handy source to learn how [...]
Archive for July, 2010
Advisory Committee Meeting: Rosiglitazone
Published July 12th, 2010 in Events, News Commentary and Uncategorized. 0 CommentsThe media is crazed with interpretations of the FDA and GSK briefing materials for the Advisory Committee meeting this week regarding the safety of Avandia (rosiglitazone). For those readers who’d like to read the original documents themselves, here are the links. July 13—14, 2010: Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee [...]
Avandia: Who Won?
Published July 15th, 2010 in News Commentary and Uncategorized. 0 CommentsThe media has been very involved in the Avandia case. Headlines or page 1 stories in the New York Times, Wall Street Journal and the British press seemed to take sides rather than report the facts (okay, I shouldn’t be surprised). Today, the day after the 2-day FDA Advisory Committee met to review the safety [...]